OBJECTIVE: To determine whether infectious trachoma can be completely eliminated from severely affected villages. DESIGN: Cross-sectional survey of 2 villages previously enrolled and monitored over 42 months as part of a larger, group-randomized clinical trial. PARTICIPANTS: A total of 758 individuals residing in 2 villages with high baseline trachoma prevalence, of a total population of 768 (98.7%). METHODS: All members of the 2 villages were offered 6 biannual mass treatments with oral azithromycin. At 42 months, each current village member was examined. The right upper tarsal conjunctiva was everted and swabbed. Samples were processed for evidence of Chlamydia trachomatis RNA. MAIN OUTCOME MEASURES: Clinical activity by World Health Organization simplified grading scale for trachoma and laboratory evidence of chlamydial RNA. RESULTS:Average antibiotic coverage over the study period was 90% and 94% in the 2 villages. Clinical trachoma activity in children aged 1 to 5 years decreased from 78% and 83% in the 2 villages before treatment to 17% and 24% at 42 months. Polymerase chain reaction (PCR) evidence of infection in the same age group decreased from 48% to 0% in both villages at 42 months. When all age groups were examined, there were zero cases with evidence of chlamydial RNA among 758 total villagers tested. CONCLUSIONS: Biannual mass distribution of azithromycin can locally eliminate ocular chlamydial infection from severely affected communities.
RCT Entities:
OBJECTIVE: To determine whether infectious trachoma can be completely eliminated from severely affected villages. DESIGN: Cross-sectional survey of 2 villages previously enrolled and monitored over 42 months as part of a larger, group-randomized clinical trial. PARTICIPANTS: A total of 758 individuals residing in 2 villages with high baseline trachoma prevalence, of a total population of 768 (98.7%). METHODS: All members of the 2 villages were offered 6 biannual mass treatments with oral azithromycin. At 42 months, each current village member was examined. The right upper tarsal conjunctiva was everted and swabbed. Samples were processed for evidence of Chlamydia trachomatis RNA. MAIN OUTCOME MEASURES: Clinical activity by World Health Organization simplified grading scale for trachoma and laboratory evidence of chlamydial RNA. RESULTS: Average antibiotic coverage over the study period was 90% and 94% in the 2 villages. Clinical trachoma activity in children aged 1 to 5 years decreased from 78% and 83% in the 2 villages before treatment to 17% and 24% at 42 months. Polymerase chain reaction (PCR) evidence of infection in the same age group decreased from 48% to 0% in both villages at 42 months. When all age groups were examined, there were zero cases with evidence of chlamydial RNA among 758 total villagers tested. CONCLUSIONS: Biannual mass distribution of azithromycin can locally eliminate ocular chlamydial infection from severely affected communities.
Authors: Thomas M Lietman; Teshome Gebre; Berhan Ayele; Kathryn J Ray; M Cyrus Maher; Craig W See; Paul M Emerson; Travis C Porco Journal: Epidemics Date: 2011-04-06 Impact factor: 4.396
Authors: Jeremy D Keenan; Craig W See; Jeanne Moncada; Berhan Ayele; Teshome Gebre; Nicole E Stoller; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman Journal: Invest Ophthalmol Vis Sci Date: 2012-01-25 Impact factor: 4.799
Authors: Jeremy D Keenan; Berhan Ayele; Teshome Gebre; Jeanne Moncada; Nicole E Stoller; Zhaoxia Zhou; Travis C Porco; Charles E McCulloch; Bruce D Gaynor; Paul M Emerson; Julius Schachter; Thomas M Lietman Journal: Clin Infect Dis Date: 2011-11-17 Impact factor: 9.079
Authors: Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Ansumana Sillah; Sandra Cohuet; Angels Natividad; Neal D E Alexander; David C W Mabey; Robin L Bailey Journal: PLoS Negl Trop Dis Date: 2010-10-05
Authors: Luis Carlos Cajas-Monson; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Charlotte A Gaydos; Sheila K West Journal: PLoS Negl Trop Dis Date: 2011-03-15
Authors: Alison H Skalet; Vicky Cevallos; Berhan Ayele; Teshome Gebre; Zhaoxia Zhou; James H Jorgensen; Mulat Zerihun; Dereje Habte; Yared Assefa; Paul M Emerson; Bruce D Gaynor; Travis C Porco; Thomas M Lietman; Jeremy D Keenan Journal: PLoS Med Date: 2010-12-14 Impact factor: 11.069
Authors: Fengchen Liu; Travis C Porco; Kathryn J Ray; Robin L Bailey; Harran Mkocha; Beatriz Muñoz; Thomas C Quinn; Thomas M Lietman; Sheila K West Journal: PLoS Negl Trop Dis Date: 2013-07-11